Encoded Therapeutics Presents New Preclinical Data at ASGCT 2026 Highlighting Precision Vector Engineering Across Neurology Programs

AI Briefing

• – Encoded Therapeutics presents new preclinical data on precision vector engineering for neurological disorders at ASGCT 2026.
• – Data highlights advancements in the company's vector engineering platform for cell-type-selective gene therapy.
• – New developments aim to improve efficacy and reduce off-target effects in treating severe neurological conditions.